# Coya Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/coya-therapeutics

- Industry: Biotechnology
- Headquarters: Houston, US
- Website: www.coyatherapeutics.com/
- Total disclosed funding: $10M
- Latest round: Series A (Dec 22, 2020)
- Investors on record: 1

## About

Founded in 2020 and based in Texas, US, Coya Therapeutics, Inc. is a clinical-stage biotechnology company developing approaches to utilizing adaptive regulatory T cells (Tregs) to target disease. The company was founded by its CEO, Howard Berman. In December 2023, Coya Therapeutics, Inc. raised USD 5.61 million in PIPE funding from Greenlight Capital. The company is listed on Nasdaq under the ticker COYA.

The company specializes in the development of therapies aimed at enhancing regulatory T cell (Treg) function. These therapies target a range of conditions, including neurodegenerative, autoimmune, and metabolic diseases. Coya’s approach focuses on multiple Treg therapeutic modalities, leveraging data, particularly in Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s disease.

Coya Therapeutics' product pipeline includes COYA 302 and COYA 301, which are Treg-enhancing biologics intended to bolster the body's regulatory T cells to combat disease; COYA 201, which comprises allogeneic Treg-derived exosomes, which are small vesicles that carry therapeutic benefits for neurodegenerative and autoimmune conditions; and COYA 101, which is an autologous Treg cell therapy where a patient's own cells are used to enhance their immune system's regulatory capabilities.

## Funding rounds

- Series A, Dec 22, 2020, $10M — Allele Capital Partners

## Investors

- Allele Capital Partners (https://capitalatlas.ai/funds/allele-capital-partners) — Series A